Skip to Content

Neuraceq Approval History

FDA Approved: Yes (First approved March 19, 2014)
Brand name: Neuraceq
Generic name: florbetaben F18
Dosage form: Injection
Company: Piramal Imaging
Treatment for: Positron Emission Tomography Imaging

Neuraceq (florbetaben F18) is a radioactive diagnostic agent indicated for PET imaging of the brain to estimate β-amyloid neuritic plaquedensity in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.

Development History and FDA Approval Process for Neuraceq

DateArticle
Mar 20, 2014Approval FDA Approves Neuraceq (florbetaben F18 injection) for PET Imaging of Beta-Amyloid Plaques

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide